Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests

European Neuropsychopharmacology

Volumn 17, Issue 3, 2007, Pages 172-179

  Belozertseva, I V ^a   Kos, T ^b   Popik, P ^b   Danysz, W ^c   Bespalov, A Y ^a  

^a PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Depression; Forced swim test; mGluR group I antagonists; Tail suspension test

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 3 ETHYL 2 METHYLQUINOLIN 6 YL 4 METHOXYCYCLOHEXYLMETHANONE METHANESULFONATE; IMIPRAMINE; JNJ 16567083; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CLIMBING; CONTROLLED STUDY; DIVING; ESCAPE BEHAVIOR; EXPERIMENTAL TEST; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; TAIL SUSPENSION TEST;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HINDLIMB SUSPENSION; IMIPRAMINE; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PYRIDINES; RATS; RATS, WISTAR; RECEPTORS, METABOTROPIC GLUTAMATE; SWIMMING; THIAZOLES;

EID: 33751190762     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2006.03.002     Document Type: Article

References (43)

1. Abel E.L., and Bilitzke P.J. A possible alarm substance in the forced swimming test. Physiol. Behav. 48 (1990) 233-239
2. Attucci S., Clodfelter G.V., Thibault O., Staton J., Moroni F., Landfield P.W., and Porter N.M. Group I metabotropic glutamate receptor inhibition selectively blocks a prolonged Ca(2+) elevation associated with age-dependent excitotoxicity. Neuroscience 112 (2002) 183-194
3. Blaabjerg M., Fang L., Zimmer J., and Baskys A. Neuroprotection against NMDA excitotoxicity by group I metabotropic glutamate receptors is associated with reduction of NMDA stimulated currents. Exp. Neurol. 183 (2003) 573-580
4. Bordi F., and Ugolini A. Group I metabotropic glutamate receptors: implications for brain diseases. Prog. Neurobiol. 59 (1999) 55-79
5. Busse C.S., Brodkin J., Tattersall D., Anderson J.J., Warren N., Tehrani L., Bristow L.J., Varney M.A., and Cosford N.D. The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 29 (2004) 1971-1979
6. Cosford N.D., Tehrani L., Roppe J., Schweiger E., Smith N.D., Anderson J., Bristow L., Brodkin J., Jiang X., McDonald I., Rao S., Washburn M., and Varney M.A. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J. Med. Chem. 46 (2003) 204-206
7. Cryan J.F., Valentino R.J., and Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci. Biobehav. Rev. 29 (2005) 547-569
8. De Pablo J.M., Parra A., Segovia S., and Guillamon A. Learned immobility explains the behavior of rats in the forced swimming test. Physiol. Behav. 46 (1989) 229-237
9. Detke M.J., and Lucki I. Detection of serotonergic and noradrenergic antidepressants in the rat forced swimming test: the effects of water depth. Behav. Brain Res. 73 (1996) 43-46
10. Detke M.J., Rickels M., and Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 121 (1995) 66-72
11. Doherty A.J., Palmer M.J., Henley J.M., Collingridge G.L., and Jane D.E. (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology 36 (1997) 265-267
12. Gasparini F., Lingenhohl K., Stoehr N., Flor P.J., Heinrich M., Vranesic I., Biollaz M., Allgeier H., Heckendorn R., Urwyler S., Varney M.A., Johnson E.C., Hess S.D., Rao S.P., Sacaan A.I., Santori E.M., Velicelebi G., and Kuhn R. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 38 (1999) 1493-1503
13. Gravius A., Pietraszek M., Schafer D., Schmidt W.J., and Danysz W. Effects of mGlu1 and mGlu5 receptor antagonists on negatively reinforced learning. Behav. Pharmacol. 16 2 (2005) 113-121
14. Heidbreder C.A., Bianchi M., Lacroix L.P., Faedo S., Perdona E., Remelli R., Cavanni P., and Crespi F. Evidence that the metabotropic glutamate receptor 5 antagonist MPEP may act as an inhibitor of the norepinephrine transporter in vitro and in vivo. Synapse 50 (2003) 269-276
15. Henry S.A., Lehmann-Masten V., Gasparini F., Geyer M.A., and Markou A. The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity. Neuropharmacology 43 (2002) 1199-1209
16. Homayoun H., Stefani M.R., Adams B.W., Tamagan G.D., and Moghaddam B. Functional interaction between NMDA and mGlu5 receptors: effects on working memory, instrumental learning, motor behaviors, and dopamine release. Neuropsychopharmacology 29 (2004) 1259-1269
17. Kendell S.F., Krystal J.H., and Sanacora G. GABA and glutamate systems as therapeutic targets in depression and mood disorders. Expert Opin. Ther. Targets 9 1 (2005) 153-168
18. Klodzinska A., Chojnacka Wojcik E., Palucha A., Branski P., Popik P., and Pilc A. Potential anti-anxiety and anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 38 (1999) 1831-1839
19. Kozela E., Pilc A., and Popik P. Inhibitory effects of MPEP, an mGluR5 antagonist, and memantine, an N-methyl-d-aspartate receptor antagonist, on morphine antinociceptive tolerance in mice. Psychopharmacology 165 (2003) 245-251
20. LeSage A.S.J., Bischoff F., Van Beijsterveldt L., Meert T., Steckler T., and Ashton D. Novel, centrally active mGluR1 antagonists: in vitro and in vivo pharmacology. Neuropharmacology 43 (2002) 295
21. O'Neil M.F., and Moore N.A. Animal models of depression: are there any?. Hum. Psychopharmacol. 18 (2003) 239-254
22. Ostroff R., Gonzales M., and Sanacora G. Antidepressant effect of ketamine during ECT. Am. J. Psychiatry 162 7 (2005) 1385-1386
23. Page M.E., Szeliga P., Gasparini F., and Cryan J.F. Blockade of the mGlu5 receptor decreases basal and stress-induced cortical norepinephrine in rodents. Psychopharmacology (Berl) 179 (2005) 240-246
24. Parsons C.G., Danysz W., and Quack G. Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect. 11 (1998) 523-569
25. Paul I.A., and Skolnick P. Glutamate and depression: clinical and preclinical studies. Ann. N.Y. Acad. Sci. 1003 (2003) 250-272
26. Pietraszek M., Gravius A., Schafer D., Weil T., Trifanova D., and Danysz W. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology 49 (2005) 73-85
27. Pietraszek M., Sukhanov I., Maciejak P., Szyndler J., Gravius A., Wisłowska A., Płaźnik A., Bespalov A.Y., and Danysz W. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur. J. Pharmacol. 514 (2005) 25-34
28. Pilc A., and Legutko B. The influence of prolonged antidepressant treatment on the changes in cyclic AMP accumulation induced by excitatory amino acids in rat cerebral cortical slices. NeuroReport 7 (1995) 85-88
29. Pin J.P., and Duvoisin R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 34 (1995) 1-26
30. Popik P., and Wrobel M. Morphine conditioned reward is inhibited by MPEP, the mGluR5 antagonist. Neuropharmacology 43 (2002) 1210-1217
31. Porsolt R.D., Anton G., Blavet N., and Jalfre M. Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur. J. Pharmacol. 47 (1978) 379-391
32. Porsolt R.D., Bertin A., and Jalfre M. Behavioural despair in rats and mice: strain differences and the effects of imipramine. Eur. J. Pharmacol. 51 (1978) 291-294
33. Schoepp D.D., Jane D.E., and Monn J.A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 38 (1999) 1431-1476
34. Skolnick P. Antidepressants for the new millenium. Eur. J. Pharmacol. 375 (1999) 31-40
35. Skolnick P., Layer R.T., Popik P., Nowak G., Paul I.A., and Trullas R. Adaptation of the N-methyl-d-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry 29 (1996) 23-26
36. Spooren W.P., Vassout A., Neijt H.C., Kuhn R., Gasparini F., Roux S., Porsolt R.D., and Gentsch C. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J. Pharmacol. Exp. Ther. 295 (2000) 1267-1275
37. Steckler T., Oliveira A.F., Van Dyck C., Van Craenendonck H., Mateus A.M., Langlois X., Lesage A.S., and Prickaerts J. Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial water maze task. Behav. Brain Res. 64 1 (2005) 52-60
38. Steckler T., Lavreysen H., Oliveira A.M., Aerts N., Van Craenendonck H., Prickaerts J., Megens A., and Lesage A.S. Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test. Psychopharmacology (Berl) 179 1 (2005) 198-206
39. Steru L., Chermat R., Thierry B., and Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85 (1985) 367-370
40. Tatarczynska E., Klodzinska A., Chojnacka-Wojcik E., Palucha A., Gasparini F., Kuhn R., and Pilc A. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol. 132 (2001) 1423-1430
41. Varty G.B., Grilli M., Forlani A., Fredduzzi S., Grzelak M.E., Guthrie D.H., Hodgson R.A., Lu S.X., Nicolussi E., Pond A.J., Parker E.M., Hunter J.C., Higgins G.A., Reggiani A., and Bertorelli R. The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology (Berl) 179 (2005) 207-217
42. Wieronska J.M., Branski P., Szewczyk B., Palucha A., Papp M., Gruca P., Moryl E., and Pilc A. Changes in the expression of metabotropic glutamate receptor 5 (mGluR5) in the rat hippocampus in an animal model of depression. Pol. J. Pharmacol. 53 (2001) 659-662
43. Wieronska J.M., Szewczyk B., Branski P., Palucha A., and Pilc A. Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids 23 (2002) 213-216